Insmed Q3 ARIKAYCE revenue $93.4M (+18% YoY); net loss $1.27/sh; adds $150M loan

INSMED Inc

2024-Q3 EPS reported -$4.27 revenue$259,265,000

ARIKAYCE global revenue $93.4M in Q3 2024, up 18% YoY; US $66.9M, Japan $21.0M, Europe/RoW $5.6M.
Net loss $220.5M ($1.27/sh) vs $158.9M ($1.11/sh) in Q3 2023; operating loss $213.4M.
NDA for brensocatib in bronchiectasis on track for Q4 2024; potential US launch mid-2025.
Amended Pharmakon loan adds $150M tranche at 9.60% fixed, maturity extends to Sept 2029.
Ended Q3 with ~$1.5B cash; redeemed $225M convertible notes; raised $371M net via ATM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.